The Results of the Use of Angiotensin Receptor Inhibitors and Neprilisin in Secondary Functional Mitral Regurgitation in Outpatient Practice

Cover Page

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Background. Morbidity and mortality in patients with functional mitral regurgitation (FMR) remains high, however, no pharmacological therapy has been proven to be effective. Aims — to study the effect of sacubitrile/valsartan and valsartan on functional mitral regurgitation in chronic heart failure. Methods. This double-blind study randomly assigned sacubitrile/valsartan or valsartan in addition to standard drug therapy for heart failure among 100 patients with heart failure with chronic FMR (secondary to left ventricular (LV) dysfunction). The primary endpoint was a change in the effective area of the regurgitation hole during the 12-month follow-up. Secondary endpoints included changes in the volume of regurgitation, the final systolic volume of the left ventricle, the final diastolic volume of the left ventricle, and the area of incomplete closure of the mitral valves. Results. The decrease in the effective area of the regurgitation hole was significantly more pronounced in the sacubitrile/valsartan group than in the valsartan group (–0.07 ± 0.066 against –0.03 ± 0.058 sm2; p = 0.018) in the treatment efficacy analysis, which included 100 patients (100%). The regurgitation volume also significantly decreased in the sacubitrile/valsartan group compared to the valsartan group (mean difference: –8.4 ml; 95% CI, from –13.2 until –1.9; р = 0.21). There were no significant differences between the groups regarding changes in the area of incomplete closure of the mitral valves and LV volumes, with the exception of the index of the final LV diastolic volume (p = 0.07). Conclusion. Among patients with secondary FMR, sacubitril/valsartan reduced MR more than valsartan. Thus, angiotensin receptor inhibitors and neprilysin can be considered for optimal drug treatment of patients with heart failure and FMR.

Full Text

Restricted Access

About the authors

Alexey S. Ryazanov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

ORCID iD: 0000-0003-2823-7774
SPIN-code: 5273-4570

MD, PhD, Professor

Russian Federation, Moscow

Konstantin I. Kapitonov

Clinical and Diagnostic Center No. 4 of the Moscow Department of Health

ORCID iD: 0000-0002-2750-0852
SPIN-code: 6331-4986


Russian Federation, Moscow

Mariya V. Makarovskaya

Clinical and Diagnostic Center No. 4 of the Moscow Department of Health

Author for correspondence.
ORCID iD: 0000-0002-2313-2159
SPIN-code: 4937-9454


Russian Federation, Moscow

Alexey A. Kudryavtsev

I.M. Sechenov First Moscow State Medical University (Sechenov University)

ORCID iD: 0000-0001-8294-5136
SPIN-code: 4403-2229


Russian Federation, Moscow


  1. Pirard LA, Carabello BA. Ischemic mitral regurgitation: Pathophysiology, outcomes and the conundrum of treatment. Eur Heart J. 2010;31:2996–3005. doi:
  2. Арутюнов А.Г., Драгунов Д.О., Арутюнов Г.П., и др. Первое открытое исследование синдрома острой декомпенсации сердечной недостаточности и сопутствующих заболеваний в Российской Федерации // Независимый регистр ОРАКУЛ-РФ. Кардиология. — 2015. — № 5. — С. 12–21. [Arutyunov AG, Dragunov DO, Arutyunov GP, et al. First Open Study of Syndrome of Acute Decompensation of Heart Failure and Concomitant Diseases in Russian Federation. Independent Registry ORAKUL. Kardiologiia. 2015;5:12–21. (In Russ.)]
  3. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., и др. Клинические рекомендации ОССН–РКО–РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН) // Диагностика, профилактика и лечение. Кардиология. — 2018. —№ 58 (S6). — С. 50–52. [Mareev VYu, Ageev FT, Arutyunov GP, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(S6):50–52. (In Russ.)] doi:
  4. Мареев Ю.В., Мареев В.Ю. Характеристика и лечение пациентов с ХСН, госпитализированных в стационар // Кардиология. — 2017. — № 57 (S4). — С. 20–30. [Mareev YuV, Mareev VYu. Characteristics and treatment of hospitalized patients with CHF. Kardiologiia. 2017;57(S4):20–30. (In Russ.)] doi:
  5. Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: Pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. 2015;65:1231–1248. doi:
  6. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–e161. doi:
  7. Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016;133:1115–1124. doi:
  8. Моисеев В.С., Кобалава Ж.Д., Моисеев С.В. Лечение болезней сердца. — М.: Медицинское информационное агентство, 2016. — 600 с. [Moiseev VS, Kobalava ZhD, Moiseev SV. Heart disease treatment. Moscow: Izdatel’stvo “Meditsinskoe informatsionnoe agentstvo”; 2016. 600 s. (In Russ.)]
  9. Кобалава Ж.Д., Павликова Е.П, Аверков О.А., и др. Первый опыт клинического применения двойного ингибитора ангиотензиновых рецепторов и неприлизина LCZ696 у больных сердечной недостаточностью со сниженной фракцией выброса // Кардиология. — 2015. — Т. 55. — № 7. — С. 14–25. [Kobalava ZhD, Pavlikova EP, Averkov OA, et al. First Experience of Clinical Application of LCZ696 — an ATl-angiotensin Receptors and Neprilysin Inhibitor — in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Kardiologiya. 2015;55(7):14–25. (In Russ.)] doi:
  10. McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. doi:
  11. Мареев В.Ю. Проект заключения Совета экспертов по хронической сердечной недостаточности // Сердечная недостаточность. — 2016. — Т. 17. — № 4 (97). — С. 291–296. [Mareev VYu. Draft conclusion of the expert Council on chronic heart failure. Zhurnal Serdechnaya Nedostatochnost’. 2016;17:4(97):291–296. (In Russ.)] doi:
  12. Solomon SD, Zile M, Pieske B, et al. Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387–1395. doi:
  13. Grayburn PA, Weissman NJ, Zamorano JL. Quantitation of mitral regurgitation. Circulation. 2012;126(16):2005–2017. doi:
  14. Nishimura RA, Vahanian A, Eleid MF, et al. Mitral valve disease–current management and future challenges. Lancet. 2016;387:1324–1334. doi:
  15. Michler RE, Rouleau JL, Al-Khalidi HR, et al. STICH Trial Investigators. Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg. 2013;146:1139–45.e6. doi:
  16. Kang D-H, Park S-J, Shin S-H, et al. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. PRIME Study. Circulation. 2019;139:1354–1365. doi:
  17. Martens P, Beliën H, Dupont M, et al. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018;36:e12435. doi:

Supplementary files

There are no supplementary files to display.



Abstract: 383

PDF (Russian): 3

Article Metrics

Metrics Loading ...



Copyright (c) 2020 Russian academy of sciences

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies